Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies

This first-in-human study aimed to assess the safety and internal radiation dosimetry of 177Lu-JH040182, a novel FAP-targeted radiopharmaceutical, in patients with FAP-positive tumors. All patients underwent screening via 68Ga-FAPI PET/CT. Those confirmed to have FAP-positive lesions on PET imaging received administration of 177Lu-JH040182, and serial-time-point SPECT images were acquired for internal radiation dosimetry calculations.

NCT Number	NCT07681141
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Patients With Advanced Metastatic FAP-Positive Tumors
Enrollment	3 participants
Start Date	2025-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-02